Literature DB >> 10743281

Developing a national system for dealing with adverse events following immunization.

U Mehta1, J B Milstien, P Duclos, P I Folb.   

Abstract

Although vaccines are among the safest of pharmaceuticals, the occasional severe adverse event or cluster of adverse events associated with their use may rapidly become a serious threat to public health. It is essential that national monitoring and reporting systems for vaccine safety are efficient and adequately coordinated with those that conventionally deal with non-vaccine pharmaceuticals. Equally important is the need for an enlightened and informed national system to be in place to deal with public concerns and rapid evaluation of the risk to public safety when adverse events occur. Described in this article is the outcome of efforts by the WHO Global Training Network to describe a simple national system for dealing with vaccine safety and with emergencies as they arise. The goals of a training programme designed to help develop such a system are also outlined.

Mesh:

Substances:

Year:  2000        PMID: 10743281      PMCID: PMC2560682     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  Immunisation safety: a priority of the World Health Organization's Department of Vaccines and Biologicals.

Authors:  P Duclos; C A Hofmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana.

Authors:  Alexander N O Dodoo; Lorna Renner; Adrianus C van Grootheest; Jerry Labadie; Kwadwo O Antwi-Agyei; Selasie Hayibor; Johannes Addison; Victoria Pappoe; Augustina Appiah-Danquah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.

Authors:  Edwin J Asturias; Melinda Wharton; Robert Pless; Noni E MacDonald; Robert T Chen; Nicholas Andrews; David Salisbury; Alexander N Dodoo; Kenneth Hartigan-Go; Patrick L F Zuber
Journal:  Vaccine       Date:  2016-05-16       Impact factor: 3.641

4.  Pharmacovigilance in vaccines.

Authors:  Salil Budhiraja; Raghuram Akinapelli
Journal:  Indian J Pharmacol       Date:  2010-04       Impact factor: 1.200

5.  Pharmacovigilance: a worldwide master key for drug safety monitoring: some additional information.

Authors:  C Patel
Journal:  J Young Pharm       Date:  2011-04

6.  Pharmacovigilance: scope for a dermatologist.

Authors:  Bhanu Prakash; Gurcharan Singh
Journal:  Indian J Dermatol       Date:  2011 Sep-Oct       Impact factor: 1.494

7.  Improving community based AEFI (Adverse Events Following Immunization) reporting rate through telephone "beep" in a Cameroon health district: a randomized field trial.

Authors:  Marcellin Tsafack; Jérôme Ateudjieu
Journal:  Pan Afr Med J       Date:  2015-12-11

8.  Knowledge, Perceptions, and Practice of Nurses on Surveillance of Adverse Events following Childhood Immunization in Nairobi, Kenya.

Authors:  Calistus Wanjala Masika; Harrysone Atieli; Tom Were
Journal:  Biomed Res Int       Date:  2016-12-19       Impact factor: 3.411

9.  Evaluation of the adverse events following immunization surveillance system in Guruve district, Mashonaland Central 2017.

Authors:  Mutata Constantine; Tshuma Cremance; Tsitsi Patience Juru; Shambira Gerald; Gombe Tafara Notion; Nsubuga Peter; Tshimanga Mufuta
Journal:  Pan Afr Med J       Date:  2018-11-22

10.  Knowledge and Perceptions of Nurse Practitioners on Adverse Events Following Immunization and Barriers to Reporting in the Central Region, Eritrea: A Cross-Sectional Study.

Authors:  Nuru Abdu; Asmerom Mosazghi; Tedros Yehdego; Eyasu H Tesfamariam; Mulugeta Russom
Journal:  Drug Healthc Patient Saf       Date:  2022-07-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.